Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $12.09, for a total transaction of $24,180.00. Following the completion of the transaction, the president now owns 2,829,260 shares in the company, valued at approximately $34,205,753.40. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, March 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.13, for a total transaction of $20,260.00.
• On Friday, March 14th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.31, for a total transaction of $24,620.00.
• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.74, for a total transaction of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total transaction of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total transaction of $20,980.00.

Gyre Therapeutics Trading Down 5.0 %

Gyre Therapeutics stock traded down $0.51 during trading hours on Friday, reaching $9.71. 261,187 shares of the stock were exchanged, compared to its average volume of 81,347. The company has a market cap of $908.97 million, a P/E ratio of 194.20 and a beta of 1.93. Gyre Therapeutics, Inc. has a twelve month low of $8.26 and a twelve month high of $19.00. The stock has a 50 day moving average of $11.31 and a two-hundred day moving average of $12.20.

Remove Ads

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03). The company had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Analysts Set New Price Targets

Separately, Noble Financial began coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They set an "outperform" rating on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC bought a new position in shares of Gyre Therapeutics in the third quarter worth about $47,000. Wells Fargo & Company MN lifted its holdings in shares of Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after acquiring an additional 913 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock worth $84,000 after acquiring an additional 1,996 shares during the last quarter. Barclays PLC lifted its holdings in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after acquiring an additional 6,855 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Gyre Therapeutics by 11.1% in the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock worth $168,000 after acquiring an additional 1,389 shares during the last quarter. Institutional investors own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.